Summit Trail Advisors LLC Acquires New Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Summit Trail Advisors LLC bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,376 shares of the specialty pharmaceutical company’s stock, valued at approximately $539,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Savant Capital LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $272,000. Thompson Investment Management Inc. grew its stake in Jazz Pharmaceuticals by 8.2% in the 4th quarter. Thompson Investment Management Inc. now owns 7,220 shares of the specialty pharmaceutical company’s stock worth $889,000 after buying an additional 550 shares in the last quarter. Moloney Securities Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth $464,000. Bleakley Financial Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 52.5% in the 4th quarter. Bleakley Financial Group LLC now owns 3,112 shares of the specialty pharmaceutical company’s stock worth $383,000 after buying an additional 1,071 shares during the last quarter. Finally, Choreo LLC raised its position in shares of Jazz Pharmaceuticals by 58.2% during the 4th quarter. Choreo LLC now owns 2,954 shares of the specialty pharmaceutical company’s stock valued at $363,000 after buying an additional 1,087 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on JAZZ shares. Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. TD Cowen cut their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Finally, Piper Sandler reiterated an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $177.00.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 5,053 shares of company stock valued at $617,442. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Up 5.2 %

Shares of JAZZ opened at $129.98 on Wednesday. The stock has a market capitalization of $7.86 billion, a P/E ratio of 18.31, a PEG ratio of 0.92 and a beta of 0.56. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a fifty day simple moving average of $122.56 and a two-hundred day simple moving average of $116.63.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.